JP2017513900A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017513900A5 JP2017513900A5 JP2016564149A JP2016564149A JP2017513900A5 JP 2017513900 A5 JP2017513900 A5 JP 2017513900A5 JP 2016564149 A JP2016564149 A JP 2016564149A JP 2016564149 A JP2016564149 A JP 2016564149A JP 2017513900 A5 JP2017513900 A5 JP 2017513900A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- sequence
- sequences
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940125644 antibody drug Drugs 0.000 claims 12
- 239000000611 antibody drug conjugate Substances 0.000 claims 7
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 claims 1
- 125000006781 (C4-C10) cycloalkylcarbonyl group Chemical group 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14305620 | 2014-04-25 | ||
| EP14305620.8 | 2014-04-25 | ||
| PCT/EP2015/059045 WO2015162291A1 (en) | 2014-04-25 | 2015-04-27 | Igf-1r antibody-drug-conjugate and its use for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017513900A JP2017513900A (ja) | 2017-06-01 |
| JP2017513900A5 true JP2017513900A5 (enExample) | 2017-08-10 |
| JP6258523B2 JP6258523B2 (ja) | 2018-01-10 |
Family
ID=50630736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016564149A Active JP6258523B2 (ja) | 2014-04-25 | 2015-04-27 | Ｉｇｆ−１ｒ抗体−薬物複合体および癌の処置のためのその使用 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US10633448B2 (enExample) |
| EP (2) | EP3134124B1 (enExample) |
| JP (1) | JP6258523B2 (enExample) |
| KR (1) | KR101795984B1 (enExample) |
| CN (1) | CN106456800B (enExample) |
| AU (1) | AU2015250759B2 (enExample) |
| BR (1) | BR112016024619A2 (enExample) |
| CA (1) | CA2946469C (enExample) |
| CY (1) | CY1121783T1 (enExample) |
| DK (1) | DK3134124T3 (enExample) |
| ES (1) | ES2727103T3 (enExample) |
| HR (1) | HRP20190888T8 (enExample) |
| HU (1) | HUE044862T2 (enExample) |
| IL (1) | IL248455B (enExample) |
| LT (1) | LT3134124T (enExample) |
| MA (2) | MA39909B1 (enExample) |
| MX (1) | MX372912B (enExample) |
| MY (1) | MY186711A (enExample) |
| PL (1) | PL3134124T3 (enExample) |
| PT (1) | PT3134124T (enExample) |
| RS (1) | RS58742B1 (enExample) |
| RU (1) | RU2692563C2 (enExample) |
| SA (1) | SA516380120B1 (enExample) |
| SI (1) | SI3134124T1 (enExample) |
| TN (1) | TN2016000472A1 (enExample) |
| UA (1) | UA120364C2 (enExample) |
| WO (1) | WO2015162291A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3134124B1 (en) * | 2014-04-25 | 2019-02-20 | Pierre Fabre Medicament | Igf-1r antibody-drug-conjugate and its use for the treatment of cancer |
| US10858423B2 (en) | 2015-10-26 | 2020-12-08 | Pierre Fabre Medicament | Composition for the treatment of IGF-1R expressing cancer |
| WO2017153432A1 (en) | 2016-03-07 | 2017-09-14 | Pierre Fabre Medicament | A new universal method to capture and analyze adcs for characterization of drug distribution and the drug-to-antibody ratio in biological samples |
| AU2019350536B2 (en) | 2018-09-27 | 2026-04-23 | Pierre Fabre Medicament | Sulfomaleimide-based linkers and corresponding conjugates |
| CN111327570B (zh) | 2018-12-14 | 2021-09-17 | 北京京东尚科信息技术有限公司 | 验证方法、装置和计算机可读存储介质 |
| EP3735991A1 (fr) | 2019-05-06 | 2020-11-11 | Pierre Fabre Medicament | Adc pour un traitement concomitant ou postérieur au docétaxel |
| BR112022019919A2 (pt) | 2020-04-02 | 2023-02-14 | Mersana Therapeutics Inc | Conjugado de anticorpo-fármaco compreendendo agonistas de sting |
| EP3909612A1 (en) | 2020-05-12 | 2021-11-17 | Life Science Inkubator Betriebs GmbH & Co. KG | Composition of nanoparticles |
| CN116635024A (zh) * | 2020-10-14 | 2023-08-22 | 维里迪安治疗公司 | 用于治疗甲状腺眼病的组合物和方法 |
| TW202228775A (zh) | 2020-10-14 | 2022-08-01 | 美商維里迪恩醫療股份有限公司 | 用於治療甲狀腺眼病之組合物及方法 |
| CA3213636A1 (en) | 2021-03-18 | 2022-09-22 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| AU2023285108A1 (en) * | 2022-06-10 | 2025-01-02 | Acelyrin, Inc. | Anti-igf-1r antibody compositions |
| EP4353220A1 (en) | 2022-10-12 | 2024-04-17 | Pierre Fabre Medicament | Use of a liquid aqueous composition for solubilization and stabilization of an antibody-drug conjugate |
| WO2024180233A1 (en) | 2023-03-02 | 2024-09-06 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | A therapeutic hpv vaccine based on validated target epitopes |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| CN121712509A (zh) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | 用于ras相关疾病或病症的组合疗法 |
| KR20260020410A (ko) * | 2023-05-31 | 2026-02-11 | 리룸 테라퓨틱스, 인크. | 세포독성 제제에 접합된 인슐린 유사 성장 인자 1 수용체 리간드를 이용한 igf-1r 관련 암의 치료 방법 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| JP3469580B2 (ja) | 1993-10-01 | 2003-11-25 | 帝国臓器製薬株式会社 | 新規なペプチド誘導体 |
| US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| MXPA06014065A (es) * | 2004-06-01 | 2007-01-31 | Genentech Inc | Conjugados de droga-anticuerpo y metodos. |
| ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
| AU2006294554B2 (en) | 2005-09-26 | 2013-03-21 | E. R. Squibb & Sons, L.L.C. | Antibody-drug conjugates and methods of use |
| AR064464A1 (es) | 2006-12-22 | 2009-04-01 | Genentech Inc | Anticuerpos anti - receptor del factor de crecimiento insulinico |
| AR065803A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento |
| TW200902554A (en) | 2007-05-08 | 2009-01-16 | Genentech Inc | Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates |
| AU2008312457B2 (en) | 2007-10-19 | 2014-04-17 | Genentech, Inc. | Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates |
| KR101674097B1 (ko) | 2008-04-11 | 2016-11-08 | 시애틀 지네틱스, 인크. | 췌장, 난소 및 다른 암의 검출 및 치료 |
| CA2754531A1 (en) | 2009-03-06 | 2010-09-30 | Seattle Genetics, Inc. | Antibody drug conjugates (adc) that bind to 24p4c12 proteins |
| WO2010146059A2 (en) * | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
| TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| WO2011130598A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
| CA2801971C (en) | 2010-06-10 | 2018-07-24 | Hans-Georg Lerchen | Novel auristatin derivatives and their use |
| ES2553874T3 (es) | 2010-09-29 | 2015-12-14 | Seattle Genetics, Inc. | N-Carboxialquil-auristatinas y su uso |
| ES3004351T3 (en) * | 2010-10-22 | 2025-03-12 | Seagen Inc | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway |
| CA2930801C (en) | 2010-11-05 | 2019-05-28 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| CA2829736C (en) | 2011-03-16 | 2020-07-21 | Seattle Genetics, Inc. | N-carboxyalkylauristatins and use thereof |
| US9150644B2 (en) * | 2011-04-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II |
| EP2714685B1 (en) | 2011-05-27 | 2016-10-19 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
| CN103717595A (zh) | 2011-05-27 | 2014-04-09 | Ambrx公司 | 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途 |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| MX363116B (es) | 2012-06-07 | 2019-03-11 | Ambrx Inc | Conjugados anticuerpo-farmaco de antigeno de membrana especifico de prostata. |
| EP4406612A3 (en) | 2012-06-19 | 2024-10-16 | Ambrx, Inc. | Anti-cd70 antibody drug conjugates |
| US20140017265A1 (en) | 2012-07-05 | 2014-01-16 | Mersana Therapeutics, Inc. | Terminally Modified Polymers and Conjugates Thereof |
| EP2885321A4 (en) | 2012-08-14 | 2016-03-30 | Angiochem Inc | CONJUGATES WITH AN ANTIBODY PART, A POLYPEPTIDE THROUGH THE BLOOD BRAIN BARRIER, AND A CYTOTOXIN |
| US20150314007A1 (en) | 2012-12-21 | 2015-11-05 | Glykos Finland Oy | Linker-payload molecule conjugates |
| FR3005051A1 (fr) | 2013-04-25 | 2014-10-31 | Pf Medicament | Derives de la dolastatine 10 et d'auristatines |
| CN106470708B (zh) | 2014-04-25 | 2019-12-31 | 皮埃尔法布雷医药公司 | 抗体-药物-缀合物和其用于治疗癌症的用途 |
| KR20220018620A (ko) * | 2014-04-25 | 2022-02-15 | 피에르 파브르 메디카먼트 | Igf-1r 항체 및 암 치료를 위한 운반체를 어드레싱하는 그의 용도 |
| EP3134124B1 (en) * | 2014-04-25 | 2019-02-20 | Pierre Fabre Medicament | Igf-1r antibody-drug-conjugate and its use for the treatment of cancer |
| US10858423B2 (en) * | 2015-10-26 | 2020-12-08 | Pierre Fabre Medicament | Composition for the treatment of IGF-1R expressing cancer |
-
2015
- 2015-04-27 EP EP15720045.2A patent/EP3134124B1/en active Active
- 2015-04-27 EP EP19154902.1A patent/EP3498301A1/en not_active Withdrawn
- 2015-04-27 PL PL15720045T patent/PL3134124T3/pl unknown
- 2015-04-27 JP JP2016564149A patent/JP6258523B2/ja active Active
- 2015-04-27 PT PT15720045T patent/PT3134124T/pt unknown
- 2015-04-27 CN CN201580033382.0A patent/CN106456800B/zh active Active
- 2015-04-27 CA CA2946469A patent/CA2946469C/en active Active
- 2015-04-27 UA UAA201611833A patent/UA120364C2/uk unknown
- 2015-04-27 LT LTEP15720045.2T patent/LT3134124T/lt unknown
- 2015-04-27 RU RU2016145444A patent/RU2692563C2/ru active
- 2015-04-27 HR HRP20190888TT patent/HRP20190888T8/hr unknown
- 2015-04-27 MA MA39909A patent/MA39909B1/fr unknown
- 2015-04-27 MY MYPI2016703874A patent/MY186711A/en unknown
- 2015-04-27 MX MX2016013704A patent/MX372912B/es active IP Right Grant
- 2015-04-27 RS RS20190615A patent/RS58742B1/sr unknown
- 2015-04-27 KR KR1020167031683A patent/KR101795984B1/ko active Active
- 2015-04-27 SI SI201530751T patent/SI3134124T1/sl unknown
- 2015-04-27 DK DK15720045.2T patent/DK3134124T3/da active
- 2015-04-27 MA MA047811A patent/MA47811A/fr unknown
- 2015-04-27 AU AU2015250759A patent/AU2015250759B2/en not_active Ceased
- 2015-04-27 WO PCT/EP2015/059045 patent/WO2015162291A1/en not_active Ceased
- 2015-04-27 HU HUE15720045 patent/HUE044862T2/hu unknown
- 2015-04-27 US US15/306,351 patent/US10633448B2/en active Active
- 2015-04-27 ES ES15720045T patent/ES2727103T3/es active Active
- 2015-04-27 BR BR112016024619A patent/BR112016024619A2/pt not_active Application Discontinuation
- 2015-04-27 TN TN2016000472A patent/TN2016000472A1/en unknown
-
2016
- 2016-10-23 SA SA516380120A patent/SA516380120B1/ar unknown
- 2016-10-23 IL IL248455A patent/IL248455B/en active IP Right Grant
-
2019
- 2019-05-15 CY CY20191100523T patent/CY1121783T1/el unknown
-
2020
- 2020-02-26 US US16/801,491 patent/US11661457B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016145444A (ru) | Конъюгат антитела против igf-1r с лекарственным средством и его применение для лечения рака | |
| JP2017513904A5 (enExample) | ||
| JP2011046732A5 (enExample) | ||
| JP2014502955A5 (enExample) | ||
| JP2020512281A5 (enExample) | ||
| JP2020502271A5 (enExample) | ||
| HRP20192254T1 (hr) | Konjugat antitijela i lijeka i njegova upotreba u liječenju karcinoma | |
| JP2017518040A5 (enExample) | ||
| JP2019531084A5 (enExample) | ||
| JP2013528569A5 (enExample) | ||
| JP2023515566A5 (enExample) | ||
| JP2011505146A5 (enExample) | ||
| JP2015509947A5 (enExample) | ||
| JP2019533719A5 (enExample) | ||
| JP2021524447A5 (enExample) | ||
| JP2017519759A5 (enExample) | ||
| JP2018536624A5 (enExample) | ||
| JP2019536740A5 (enExample) | ||
| JP2019524701A5 (enExample) | ||
| JP2010535713A5 (enExample) | ||
| JP2015528818A5 (enExample) | ||
| JP2018527884A5 (enExample) | ||
| JP2013519364A5 (enExample) | ||
| JP2016531914A5 (enExample) | ||
| JP2013505944A5 (enExample) |